Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/17.OJtTHmzH.js ...

Twilio stock is one of the best-performing stocks Friday after the tech company revealed its three-year profit forecast at an ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Follow along for live updates on stocks, bonds and other markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk A/S (NYSE:NVO) today announced positive early-stage trial results for its amycretin obesity drug. The treatment, ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...